Temat: "Glucose" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Prediabetic Dysglycemia: Call for Action.
Autorzy :: Sjöholm Å; Department of Internal Medicine, Division of Endocrinology and Diabetology, Gavle Hospital, SE-80324 Gavle, Sweden.; Pokaż więcej
Źródło :: Current diabetes reviews [Curr Diabetes Rev] 2021; Vol. 17 (1), pp. 21-25.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/epidemiology
Glucose Intolerance*
Prediabetic State*/epidemiology
Prediabetic State*/therapy
Blood Glucose ; Glucose Tolerance Test ; Humans ; Risk Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Early eGFR decline after SGLT2i initiation: knowns and unknowns.
Autorzy :: Gregg LP; Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Section of Nephrology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, USA; VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas, USA.
Navaneethan SD; Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Section of Nephrology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, USA; VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas, USA; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA. Electronic address: .; Pokaż więcej
Źródło :: Kidney international [Kidney Int] 2021 Mar; Vol. 99 (3), pp. 548-550.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Benzhydryl Compounds ; ErbB Receptors ; Glomerular Filtration Rate ; Glucose ; Glucosides ; Humans ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: [SGLT2 inhibitors in diabetic and non-diabetic nephropathies].
Autorzy :: Scheen M; Service de néphrologie, HUG, 1211 Genève 14.
Zanchi A; Service d'endocrinologie, CHUV, 1011 Lausanne.
Martin PY; Service de néphrologie, HUG, 1211 Genève 14.
De Seigneux S; Service de néphrologie, HUG, 1211 Genève 14.; Pokaż więcej
Transliterated Title :: Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques.
Źródło :: Revue medicale suisse [Rev Med Suisse] 2021 Feb 24; Vol. 17 (727), pp. 378-382.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2*
Diabetic Nephropathies*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Hypoglycemic Agents/therapeutic use ; Sodium-Glucose Transporter 2
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
Autorzy :: Meyer EJ; The Queen Elizabeth Hospital, Adelaide, SA.; University of Adelaide, Adelaide, SA.
Thiruvenkatarajan V; The Queen Elizabeth Hospital, Adelaide, SA.; University of Adelaide, Adelaide, SA.
Jesudason D; The Queen Elizabeth Hospital, Adelaide, SA.; University of Adelaide, Adelaide, SA.; Pokaż więcej
Źródło :: The Medical journal of Australia [Med J Aust] 2021 Feb; Vol. 214 (2), pp. 93-93.e1. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji :: Letter; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Diabetic Ketoacidosis*/chemically induced
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Therapeutic transformation for diabetic kidney disease.
Autorzy :: Tuttle KR; Providence Medical Research Center, Providence Health Care, Spokane, Washington, USA; Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, Washington, USA. Electronic address: .
Cherney DZI; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Nephrology Division, University of Toronto, Toronto, Ontario, Canada.; Pokaż więcej
Źródło :: Kidney international [Kidney Int] 2021 Feb; Vol. 99 (2), pp. 301-303.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*
Diabetic Nephropathies*/drug therapy
Diabetic Nephropathies*/etiology
Heart Failure*
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Albuminuria/drug therapy ; Endothelin Receptor Antagonists ; Glomerular Filtration Rate ; Glucose ; Humans ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.
Autorzy :: Hamblin PS; Western Health, Melbourne, VIC.; University of Melbourne, Melbourne, VIC.
Wong R; Box Hill Hospital, Melbourne, VIC.
Bach LA; Alfred Hospital, Melbourne, VIC.; Monash University, Melbourne, VIC.; Pokaż więcej
Źródło :: The Medical journal of Australia [Med J Aust] 2021 Feb; Vol. 214 (2), pp. 94-94.e1. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji :: Letter; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Diabetic Ketoacidosis*/chemically induced
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Increased glucose metabolism in Arid5b skeletal muscle is associated with the down-regulation of TBC1 domain family member 1 (TBC1D1).
Autorzy :: Okazaki Y; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA. .; Department of Molecular and Applied Bioscience, Graduate School of Biosphere Science, Hiroshima University, Higashi-Hiroshima, Hiroshima, Japan. .; Department of Central Research Institute, Wakunaga Pharmaceutical Co., Ltd., Akitakata, Hiroshima, Japan. .
Murray J; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Ehsani A; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Clark J; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Whitson RH; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Hirose L; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Yanaka N; Department of Molecular and Applied Bioscience, Graduate School of Biosphere Science, Hiroshima University, Higashi-Hiroshima, Hiroshima, Japan.
Itakura K; Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.; Pokaż więcej
Źródło :: Biological research [Biol Res] 2020 Oct 06; Vol. 53 (1), pp. 45. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :: Journal Article
MeSH Terms :: Glucose*/metabolism
Muscle, Skeletal*/metabolism
DNA-Binding Proteins/*genetics
GTPase-Activating Proteins/*genetics
Transcription Factors/*genetics
Animals ; Biological Transport ; Down-Regulation ; Glucose Transporter Type 1/metabolism ; Glucose Transporter Type 4/metabolism ; Mice ; Mice, Knockout
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Consumption of a Beverage Containing Aspartame and Acesulfame K for Two Weeks Does Not Adversely Influence Glucose Metabolism in Adult Males and Females: A Randomized Crossover Study.
Autorzy :: Kim Y; Department of Food and Nutrition, Institute of Agriculture and Life Science, Gyeongsang National University, Jinju 52828, Korea.
Keogh JB; UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Clifton PM; UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.; Pokaż więcej
Źródło :: International journal of environmental research and public health [Int J Environ Res Public Health] 2020 Dec 04; Vol. 17 (23). Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Aspartame*/adverse effects
Blood Glucose*
Diabetes Mellitus, Type 2*
Sweetening Agents*/adverse effects
Thiazines*/adverse effects
Adult ; Beverages ; Cross-Over Studies ; Female ; Glucose ; Humans ; Insulin ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.
Autorzy :: Ekanayake P; Veterans Affairs Medical Center, San Diego, CA, USA.; Department of Medicine, University of California at San Diego, San Diego School of Medicine, San Diego, USA.
Hupfeld C; Veterans Affairs Medical Center, San Diego, CA, USA.; Department of Medicine, University of California at San Diego, San Diego School of Medicine, San Diego, USA.
Mudaliar S; Veterans Affairs Medical Center, San Diego, CA, USA. .; Department of Medicine, University of California at San Diego, San Diego School of Medicine, San Diego, USA. .; Diabetes/Metabolism Section, VA San Diego HealthCare System, 3350 La Jolla Village Drive (Mail Code: 111G), San Diego, CA, 92161, USA. .; Pokaż więcej
Źródło :: Current diabetes reports [Curr Diab Rep] 2020 Nov 23; Vol. 20 (12), pp. 74. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Glucose ; Humans ; Hypoglycemic Agents/therapeutic use ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Review of Intravenous and Subcutaneous Electronic Glucose Management Systems for Inpatient Glycemic Control.
Autorzy :: Ekanayake PS; Department of Internal Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, San Diego, CA, USA. .
Juang PS; Department of Internal Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, San Diego, CA, USA.
Kulasa K; Department of Internal Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, San Diego, CA, USA.; Pokaż więcej
Źródło :: Current diabetes reports [Curr Diab Rep] 2020 Nov 09; Vol. 20 (12), pp. 68. Date of Electronic Publication: 2020 Nov 09.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Glucose*
Inpatients*
Blood Glucose ; Electronics ; Glycemic Control ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Estimated Treatment Effects of Tight Glycaemic Targets in Mild Gestational Diabetes Mellitus: A Multiple Cut-Off Regression Discontinuity Study Design.
Autorzy :: Song D; Internal Medicine Service, Ballarat Base Hospital, Ballarat, Victoria 3350, Australia.; Dorevitch Pathology, Chemical Pathology, Melbourne, Victoria 3084, Australia.; School of Medicine, Deakin University, Geelong, Victoria 3217, Australia.
Hurley JC; Internal Medicine Service, Ballarat Base Hospital, Ballarat, Victoria 3350, Australia.; Department of Rural Health|Melbourne Medical School, University of Melbourne, Ballarat, Victoria 3350, Australia.
Lia M; Peninsula Health, Melbourne, Victoria 3199, Australia.; Pokaż więcej
Źródło :: International journal of environmental research and public health [Int J Environ Res Public Health] 2020 Oct 22; Vol. 17 (21). Date of Electronic Publication: 2020 Oct 22.
Typ publikacji :: Journal Article
MeSH Terms :: Blood Glucose*/analysis
Blood Glucose*/metabolism
Diabetes, Gestational*/therapy
Cesarean Section/statistics & numerical data ; Cohort Studies ; Female ; Glucose Tolerance Test ; Humans ; Infant, Newborn ; Pregnancy ; Retrospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Circulating Retinol-Binding Protein 4 Is Inversely Associated With Pancreatic β-Cell Function Across the Spectrum of Glycemia.
Autorzy :: Huang R; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Yin S; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Ye Y; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Chen N; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Luo S; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Xia M; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China .; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Zhao L; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China .; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.; Pokaż więcej
Źródło :: Diabetes care [Diabetes Care] 2020 Jun; Vol. 43 (6), pp. 1258-1265. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Diabetes Mellitus, Type 2*/blood
Diabetes Mellitus, Type 2*/physiopathology
Glucose Intolerance*/blood
Glucose Intolerance*/physiopathology
Prediabetic State*/blood
Prediabetic State*/physiopathology
Blood Glucose/*metabolism
Insulin-Secreting Cells/*physiology
Retinol-Binding Proteins, Plasma/*metabolism
Adult ; Case-Control Studies ; Female ; Glucose Tolerance Test ; Humans ; Insulin/metabolism ; Insulin Resistance/physiology ; Insulin Secretion/physiology ; Male ; Middle Aged ; Retinol-Binding Proteins, Plasma/analysis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now.
Autorzy :: Taliercio JJ; Program Director, Nephrology and Hypertension Fellowship, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study .
Thomas G; Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
Nakhoul GN; Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study.
Vachharajani TJ; Department of Hypertension and Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic; Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
Mehdi A; Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.; Pokaż więcej
Źródło :: Cleveland Clinic journal of medicine [Cleve Clin J Med] 2020 Dec 31; Vol. 88 (1), pp. 59-63. Date of Electronic Publication: 2020 Dec 31.
Typ publikacji :: Editorial; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Diabetic Nephropathies*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Hypoglycemic Agents/therapeutic use ; Sodium-Glucose Transporter 2
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
Autorzy :: Liakos A; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).
Tsapas A; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).
Bekiari E; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).; Pokaż więcej
Źródło :: Annals of internal medicine [Ann Intern Med] 2020 Dec 15; Vol. 173 (12), pp. JC70.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Diabetic Ketoacidosis*/chemically induced
Dipeptidyl-Peptidase IV Inhibitors*/adverse effects
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Cohort Studies ; Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Let's Be More Sensitive-How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes.
Autorzy :: Pratley R; AdventHealth Diabetes Institute, Orlando, Florida.; AdventHealth Translational Research Institute, Orlando, Florida.; Johns Hopkins University School of Medicine, Baltimore, Maryland.; Pokaż więcej
Źródło :: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2020 Dec 01; Vol. 105 (12).
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Glucagon-Like Peptide-1 Receptor ; Glucose ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Chronic Exposure to Environmental Level Phenanthrene Induces Non-Obesity-Dependent Insulin Resistance in Male Mice.
Autorzy :: Fang L; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.
Guo J; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.
Wang Q; College of Environment & Ecology, Xiamen University, Xiamen 361102, PR China.
Ou K; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.
Zou M; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.
Lv L; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.
Chen M; College of Environment & Ecology, Xiamen University, Xiamen 361102, PR China.
Wang C; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361102, PR China.; Pokaż więcej
Źródło :: Environmental science & technology [Environ Sci Technol] 2020 Dec 01; Vol. 54 (23), pp. 15225-15234. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Glucose Intolerance*
Insulin Resistance*
Phenanthrenes*/toxicity
Adiponectin ; Animals ; Blood Glucose ; Insulin ; Male ; Mice
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA 1c and SBP and may reduce body weight.
Autorzy :: Tanner M; NYU Grossman School of Medicine, New York, New York, USA (M.T.).; Pokaż więcej
Źródło :: Annals of internal medicine [Ann Intern Med] 2020 Nov 17; Vol. 173 (10), pp. JC52.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Pharmaceutical Preparations*
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Symporters*
Blood Glucose ; Body Weight ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor ; Humans ; Hypoglycemic Agents/therapeutic use ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Safety concerns of sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: A real-world study from the perspective of the Food and Drug Administration Adverse Event Reporting System.
Autorzy :: Zhou X; Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Zhou Y; Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Li X; Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Xiao X; Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.; Pokaż więcej
Źródło :: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Nov; Vol. 22 (11), pp. 2204-2206. Date of Electronic Publication: 2020 Aug 07.
Typ publikacji :: Letter; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :: Diabetes Mellitus, Type 1*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Symporters*
Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium ; United States/epidemiology ; United States Food and Drug Administration
: Raport

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
Autorzy :: Griffin TP; Galway University Hospitals, Galway, Ireland (T.P.G., S.F.D.).
Dinneen SF; Galway University Hospitals, Galway, Ireland (T.P.G., S.F.D.).; Pokaż więcej
Źródło :: Annals of internal medicine [Ann Intern Med] 2020 Oct 20; Vol. 173 (8), pp. JC40.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetic Ketoacidosis*/chemically induced
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Symporters*
Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Randomized Controlled Trials as Topic ; Sodium
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Autorzy :: Khan MS; Department of Medicine, Cook County Health and Hospital System, Chicago, IL, USA.
Vaduganathan M; Heart and Vascular Center, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. .; Pokaż więcej
Źródło :: Current diabetes reports [Curr Diab Rep] 2020 Oct 11; Vol. 20 (11), pp. 63. Date of Electronic Publication: 2020 Oct 11.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Heart Failure*/drug therapy
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Aged ; Glucose ; Humans ; Sodium ; Stroke Volume
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Glucose"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język